Mussalem Congenital Heart Defect Alliance Blue-Sky Therapeutics

If you are interested in the following opportunity, please contact Amy Cook at [email protected].

• LOI Due: August 17, 2026
• Submission Due: November 9, 2026
• Amount: $350,000
• Project Period: Two years (12.5% indirect costs)

This RFP was created to support bold, early-stage research that could lead to the next generation of non-device treatments for congenital heart defects. We are confident that many of the ambitious ideas out there that could revolutionize CHD treatment are too early or too innovative to receive traditional funding today. This RFP to seek out such projects and researchers that can generate the first evidence needed to move promising discoveries toward larger studies, industry partnerships, and ultimately new treatments for patients. We are seeking projects that have the potential to prevent congenital heart defects, correct or modify its underlying causes, slow disease progression, reduce lifelong complications, or improve the lives of people living with CHD. Moreover, we are inviting researchers from across medicine and science – not just those already focusing on CHD – to apply their expertise and innovative ideas to one of medicine’s most underserved fields.